Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma

Bánfalvi, Teodóra; Gilde, Katalin; Gergye, M.; Boldizsár, M.; Kremmer, T.; Ottó, Szabolcs

doi:10.1016/s0959-8049(02)00487-2

Cited by 26 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23,26,30,33 Nevertheless, our findings also hint some considerations that suggest caution in interpreting this favorable outcome and might pave the way to design more informative studies.…”

Section: Discussionmentioning

confidence: 59%

“…[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]48 In 2 cases, 26,29 the Authors reported survival analysis separately for 2 subpopulations that differed by TNM stage: since these subpopulations were completely independent, we considered them separately (Table I).…”

Section: Characteristics Of Identified Studiesmentioning

confidence: 99%

“…[13][14][15] The prognostic potential of S100B serum levels is supported by many reports in the literature. [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] Nevertheless, some investigators found no association between S100B detection and patients' survival 26,29 ; moreover, others reported that S100B has a prognostic value at univariate but not multivariate survival analysis, 38 which would rule out the value of this biomarker as a prognostic factor independent of the already established prognostic power of the TNM staging system.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

Mocellin

Zavagno

Nitti

2008

Intl Journal of Cancer

View full text Add to dashboard Cite

S100B protein detected in the serum of patients with cutaneous melanoma has been long reported as a prognostic biomarker. However, no consensus exists on its implementation in the routine clinical setting. This study aimed to comprehensively and quantitatively summarize the evidence on the suitability of serum S100B to predict patients' survival. Twenty-two series enrolling 3393 patients with TNM stage I to IV cutaneous melanoma were reviewed. Standard meta-analysis methods were applied to evaluate the overall relationship between S100B serum levels and patients' survival (meta-risk). Serum S100B positivity was associated with significantly poorer survival (hazard ratio [HR] 5 2.23, 95% CI: 1.92-2.58, p < 0.0001). Between-study heterogeneity was significant, which appeared to be related mainly to dissemination bias and the inclusion of patients with stage IV disease. Considering stage I to III melanoma (n 5 1594), the meta-risk remained highly significant (HR 5 2.28, 95% CI: 1.8-2.89; p < 0.0001) and studies' estimates were homogeneous. Subgroup analysis of series reporting multivariate survival analysis supported S100B as a prognostic factor independent of the TNM staging system. Our findings suggest that serum S100B detection has a clinically valuable independent prognostic value in patients with melanoma, with particular regard to stage I-III disease. Further investigation focusing on this subset of patients is justified and warranted before S100B can be implemented in the routine clinical management of melanoma.

show abstract

“…23,26,30,33 Nevertheless, our findings also hint some considerations that suggest caution in interpreting this favorable outcome and might pave the way to design more informative studies.…”

Section: Discussionmentioning

confidence: 59%

Section: Characteristics Of Identified Studiesmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

Mocellin

Zavagno

Nitti

2008

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…В ряде исследований показано, что при прогрессировании меланомы (до обна-ружения метастазов) увеличение маркера 5-S-CD пред-шествует изменению основных показателей -феоме-ланина и белка S100B [20]. В России указанный маркер не исследуется.…”

Section: диагностикаunclassified

Course Peculiarities of Neurocutaneous Melanosis in Children

Прыгунова¹,

Karpovich²,

Чернигина³

et al. 2016

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

“…Among the known plasmatic biomarkers of melanoma, 5-S-l-cysteinyl-l-dopa (5-SCD) seems to constitute an excellent detector of metastasis and parameter of disease progression, showing significant elevation with the occurrence of metastasis and with the progression of the disease earlier than physical, radiological or other laboratory investigations [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Development of a mass spectrometry method for the determination of a melanoma biomarker, 5-S-cysteinyldopa, in human plasma using solid phase extraction for sample clean-up

Martin

Chiap²,

Paquet

et al. 2007

Journal of Chromatography A

View full text Add to dashboard Cite

5-S-cysteinyldopa is a well-known pigment intermediate and analysis of its plasma concentration is interesting for the early diagnosis, as well as for evaluation of treatment and follow-up of malignant melanoma. A determination method of 5-SCD in human plasma was developed using solid phase extraction (SPE) on disposable cartridges and liquid chromatography electrospray mass spectrometry (LC-ESI-MS-MS). Compound's sensitivity to light and oxidation requires the addition of anti-oxidative agents (AO), to work in acidic media at 4• C and to avoid light exposure of samples since blood collection. Different solid phases involving covalent binding to phenylboronic groups or dual retention mechanisms were evaluated and extraction cartridges containing both hydrophobic and strong cation exchange functionalities were finally selected. The LC separation of 5-SCD from endogenous catecholamines was achieved by gradient elution on a C18 stationary phase. 5-SCD was detected by multiple reaction monitoring (MRM) performed on ES(+) generated ions. Finally, the method was prevalidated in the lower ng/ml range. Good results with respect to accuracy, trueness and precision were obtained.

show abstract

Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma

Cited by 26 publications

References 21 publications

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

Course Peculiarities of Neurocutaneous Melanosis in Children

Development of a mass spectrometry method for the determination of a melanoma biomarker, 5-S-cysteinyldopa, in human plasma using solid phase extraction for sample clean-up

Contact Info

Product

Resources

About